Key result
Parenteral chondroitin sulfate lacks sufficient efficacy and safety data in osteoarthritis patients with CV risk.
Answers are grounded in this paper and cite their sources.
The purpose of the review of scientific medical literature was to evaluate the data of the epidemiology of osteoarthritis (OA) and cardiovascular diseases (CVD) with the analysis of risk factors, pathophysiological and pathobiochemical mechanisms of the relationship between OA and the risk of developing CVD in the presence of chronic pain, modern strategies for screening and management of this cohort of patients, the mechanism of action and pharmacological effects of chondroitin sulfate (CS). Conclusions were drawn about the need for additional clinical and observational studies of the efficacy and safety of the parenteral form of CS (Chondroguard) in patients with chronic pain in OA and CVD, improvement of clinical recommendations for the treatment of chronic pain in patients with OA and cardiovascular risk, with special attention to interventions that eliminate mobility restrictions in patients and the inclusion of basic and adjuvant therapy with DMOADs to achieve the goals of multipurpose monotherapy in patients with contraindications to standard therapy drugs.
No takes yet. Share an insight, caveat, or question.
Сарвилина et al. (2023) conducted a review in Osteoarthritis and Cardiovascular Diseases. Chondroitin sulfate (Chondroguard) was evaluated. A review of the literature highlights the need for further studies on the efficacy and safety of parenteral chondroitin sulfate in patients with chronic pain from osteoarthritis and cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: